Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Investing.com -- Shares of Amgen (NASDAQ: NASDAQ: AMGN) dropped 12% Tuesday following the release of Phase 2 trial results ...

Studies show that investors who cultivate emotional intelligence through structured approaches - such as maintaining ...

Seasonal analysis involves the study of how the price of an asset behaves at certain times of the year. The “Santa Claus ...

As Oswego keeps booming, village officials are looking at the results of a new housing study that offers recommendations to ...

Medtronic plc MDT recently announced new data for the Evolut Transcatheter Aortic Valve Replacement System (TAVR) at PCR ...

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...

The AXS Knowledge Leaders ETF has a unique investment approach, focusing on innovative global companies with strong R&D and ...

Key Takeaways A new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study. Still, AMGN ...

Imagine you have just prepared what you think is a delicious homemade meal for your partner, and you eagerly watch as she ...

EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer’s study missDon't Miss our Black Friday Offers:Unlock your investing ...

Off-plan segment in Dubai’s residential market sets positive momentum with 50.3% YoY growth in Q3; secondary market sales rise 44.3% in Abu Dhabi ...